DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results - Company will host a business update conference call on

Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results

Company will host a business update conference call on September 25, 2018 at 4:30 PM Eastern Time -

British Columbia and MENLO PARK, California, September 24, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar"

or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial

results for the year ended June 30, 2018. DelMar executive management will host a business update conference call for investors,

analysts and other interested parties on September 25, 2018 at 4:30 p.m. Eastern Time.

past fiscal year has been an instrumental period for the Company on both corporate and clinical development fronts," commented

Saiid Zarrabian, President and Chief Executive Officer. "Moving forward, we are now a streamlined organization well positioned

to advance VAL-083's two Phase 2, biomarker-driven, clinical trials for MGMT-unmethylated GBM while evaluating combination

therapies for this novel, first-in-class, DNA-targeting, small molecule, and in concert, ramping-up efforts to explore strategic

opportunities to enhance shareholder value."

further details on the Company's operating and financial results, as well as more detail about its updated strategy, refer

to DelMar's Form 10-K filed with the SEC on September 24, 2018: http://ir.delmarpharma.com/all-sec-filings.

will host a conference call to discuss its financial results for the year ended June 30, 2018 and provide a corporate update on

September 25, 2018, at 4:30 p.m. Eastern Time. For both "listen-only" participants and those who wish to take part

in the question and answer portion of the call, the telephone Dial-in Number is 1-877-876-9177 (toll free) with Conference ID

replay of the conference call will be available on the IR Calendar of the Investors section of the Company's

website at www.delmarpharma.com and will be archived for 30 days.

OF FINANCIAL RESULTS FOR THE YEAR ENDED JUNE 30, 2018

June 30, 2018, the Company had combined cash and cash equivalents and clinical trial deposits on hand of approximately $6.9 million.

the year ended June 30, 2018, the Company reported a net loss of $11,138,312 or $0.54 per share, compared to a net loss of $8,081,764,

or $0.74 per share, for the year ended June 30, 2017.

following represents selected financial information as of June 30, 2018. The Company's financial information has been prepared

in accordance with U.S. GAAP and this selected information should be read in conjunction with DelMar's consolidated financial

statements and management's discussion and analysis, as filed.

financial statements as filed with the U.S. Securities Exchange Commission can be viewed on the company's website at: http://ir.delmarpharma.com/all-sec-filings.

Statement of Operations Data

and development expenses increased to $7,132,952 during the year ended June 30, 2018, compared to $5,003,640 for the year ended

June 30, 2017. The increase was partially due to manufacturing costs for drug product as well as ongoing study costs for the Company's

two Phase 2, biomarker-driven clinical studies. During the year ended June 30, 2018, the Company undertook site initiation and

enrollment for its now parked STAR-3, Phase 3 study in GBM. During the year ended June 30, 2018, the Company recognized certain

costs related to the parking of the trial.

and administrative expenses increased in the year ended June 30, 2018 to $4,041,711 from $3,317,189 for the year ended June 30,

2017, largely due to an increase in professional fees and personnel costs.

DelMar Pharmaceuticals, Inc.

is focused on the development and commercialization of new therapies for cancer patients who have limited or no treatment options.

By focusing on understanding tumor biology and mechanisms of treatment resistance, the Company identifies biomarkers to personalize

new therapies in indications where patients are failing, or are unable to tolerate, standard-of-care treatments.

Company's current pipeline is based around VAL-083, a "first-in-class," small-molecule chemotherapeutic with a

novel mechanism of action that has demonstrated clinical activity against a range of cancers including central nervous system,

ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in U.S. clinical trials sponsored by the National

Cancer Institute (NCI). Based on DelMar's internal research programs, and these prior NCI-sponsored clinical studies, the

Company is conducting clinical trials to support the development and commercialization of VAL-083 to solve significant unmet medical

is being studied in two collaborator-supported, biomarker-driven, Phase 2 clinical trials for MGMT-unmethylated GBM. Overcoming

MGMT-mediated resistance represents a significant unmet medical need in the treatment of GBM. In addition, DelMar has announced

the allowance of a separate IND for VAL-083 as a potential treatment for platinum-resistant ovarian cancer.

information on DelMar's clinical trials can be found on clinicaltrials.gov: https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs

additional information, please visit http://delmarpharma.com/; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com

with the Company on Twitter, LinkedIn, Facebook, and Google+.

statements contained in this press release that do not describe historical facts may constitute forward-looking statements as

that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein

are based on current expectations but are subject to a number of risks and uncertainties. The factors that could cause actual

future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating

to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the

Company's products and technology; the availability of substantial additional funding for the Company to continue its operations

and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research,

product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified

and described in more detail in the Company's filings with the SEC, including, the Company's Annual Report on Form

10-K for the year ended June 30, 2018, the Company's Quarterly Reports on Form 10-Q and the Company's Current Reports